US FDA accepts Viatris’ sNDA of MR-141 to review for treatment of presbyopia: Pittsburgh Saturday, February 28, 2026, 12:00 Hrs [IST] Viatris Inc, US-headquartered global health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results